Arthur Bergman - Concepedia

Author

Arthur Bergman

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

A BERGMAN, A Bergman, A. Bergman, ARTHUR BERGMAN, Arthur Bergman, Arthur J Bergman, Arthur J. Bergman, Auke T. Bergeman, Å. Bergman

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Pfizer (United States)United States Military Academy Pfizer (United Kingdom)

About

Arthur Bergman is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	2.3K
2	Health Sciences	7	7	535
3	Biochemistry	4	4	83
4	Allergy	2	2	89
5	Natural Sciences	1	1	26

Arthur Bergman

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses Gary Herman, C. Melinda Stevens, Koen Vandyck, Clinical Pharmacology & Therapeutics	2005	514
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes Gary Herman, Arthur Bergman, Catherine Stevens, The Journal of Clinical Endocrinology & Metabolism	2006	498
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Rajesh Krishna, Matt S. Anderson, Arthur Bergman, The Lancet Metabolic SyndromeHypertensionHealthy IndividualsLipid DisorderCardiovascular Disease	2007	276
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers Arthur Bergman, Catherine Stevens, Yanyan Zhou, Clinical Therapeutics Pharmacological StudyMedicineHealthy Male VolunteersPlacebo-controlled StudyPharmacotherapy	2006	265
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez, Nature Medicine ObesityMetabolic SyndromeDgat2 InhibitorHepatologyAcc Inhibitor	2021	207
Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor Arthur Bergman, Josée Côté, Bingming Yi, Diabetes Care Healthy SubjectsPharmacotherapyPharmacokineticsRenal FunctionRenal Excretion	2007	194
Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects Gary Herman, Arthur Bergman, Fang Liu, The Journal of Clinical Pharmacology Middle‐aged Obese SubjectsPharmacotherapyInsulin SignalingObesityMetabolic Syndrome	2006	184
Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein Xiaoyan Chu, Kelly Bleasby, Jocelyn Yabut, Journal of Pharmacology and Experimental Therapeutics	2007	175
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman, Clinical Pharmacology & Therapeutics	2022	150
Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans Stella Vincent, James R. Reed, Arthur Bergman, Drug Metabolism and Disposition	2007	148

Page 1